Research progress of diabetic retinopathy with dyslipidemia

Authors: Zhao Mengya,  Xu Xun

DOI: 10.3760/cma.j.issn.2095-0160.2017.07.017
Published 2017-07-10
Cite as Chin J Exp Ophthalmol, 2017,35(07): 655-659.

Abstract

Diabetic retinopathy (DR) is one of the major microvascular complications of diabetes, it is the most common cause of preventable blindness in diabetic adults in developed countries.Dyslipidemia, a systemic disease, is one of the most important risk factors for cardiovascular disease.Patients with diabetes are susceptibly suffering from dyslipidemia.Many studies have shown that dyslipidemia can accelerate the progression of DR and aggravate the condition of DR, making the treatment of DR more difficult.The study on the mechanism of dyslipidemia aggravating DR provides a new way to treat and prevent DR by improving dyslipidemia.Current researches have shown that dyslipidemia may accelerate the progression of DR by exacerbating mitochondrial damage, insulin resistance, inflammatory response, and PKC/AGE pathway.Studies on lipid-lowering drugs, such as statins and fibrates and other lipid-lowering measures have shown that lipid-lowering is positive in the treatment of DR.This review summarizes the research progress of DR with dyslipidemia from the clinical features, potential mechanism and the effect of lipid-lowering measures on DR.

Key words:

Diabetic retinopathy; Dyslipidemia; Lipid-lowering therapy

Contributor Information

Zhao Mengya
Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai 200080, China
Xu Xun
(Read 71 times, 1 visits today)
Updated: September 4, 2019 — 1:13 pm